• Molecular NameAmifostine
  • Synonymamifostine; Amifostine Ethiofos; Aminopropylaminoethyl Thiophosphate; Apaetp; Ethiofos; Gammaphos; SAPEP; WR-1065
  • Weight214.226
  • Drugbank_IDDB01143
  • ACS_NO20537-88-6
  • Show 3D model
  • LogP (experiment)-1.07
  • LogP (predicted, AB/LogP v2.0)-2.28
  • pka10.14, 7.26
  • LogD (pH=7, predicted)-5.29
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.23
  • LogSw (predicted, AB/LogsW2.0)697.02
  • Sw (mg/ml) (predicted, ACD/Labs)114.57
  • No.of HBond Donors5
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds7
  • TPSA130.69
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA cytoprotective adjuvant used in cancer chemotherapy involving DNA-binding chemotherapeutic agents.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding4.0
  • Volume of distribution (VD)3.5 and 7 L
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is metabolised in the liver, by alkaline phosphatase, to the active free thiol metabolite, S-2-(3-aminopropylamino)-ethanethiol, WR-1065, and the inactive WR-33278 metabolite.
  • Half life8 min
  • Excretion<4% of the parent drug and metabolites are excreted in urine, WR-1065 is found in bone marrow.
  • Urinary ExcretionN/A
  • ClerancePlasma clearance, 2.17 L/min.
  • ToxicityHypotension, nausea, vomiting. LD50 (mouse)=1000
  • LD50 (rat)N/A
  • LD50 (mouse)N/A